sunitinib + olaparib + tocilizumab

sunitinib + olaparib + tocilizumab is a combination therapy consisting of three distinct pharmacological agents: sunitinib, a multi-targeted tyrosine kinase inhibitor; olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor; and tocilizumab, an interleukin-6 (IL-6) receptor antagonist. Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, to suppress tumor angiogenesis and proliferation. Olaparib targets PARP1 and PARP2 enzymes to impede DNA repair, particularly in tumors with homologous recombination deficiency (HRD). Tocilizumab is a monoclonal antibody that binds to the IL-6 receptor, blocking pro-inflammatory signaling that can contribute to tumor progression and treatment resistance. While these agents are individually established in oncology and immunology, this specific triple combination is not a recognized clinical program and appears to be a misidentification of a trial evaluating sunitinib and olaparib in combination with the immune checkpoint inhibitors iparomlimab and tuvonralimab for advanced ovarian cancer.